Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

▎药明康德内容团队编辑今日，阿斯利康（AstraZeneca）公司公布了在研口服GLP-1疗法AZD5004，在患有2型糖尿病的肥胖患者中进行的1期临床试验的最新结果。数据显示，这款在研疗法在治疗4周后将患者体重减轻5.8%，并且改善患者的血糖指标。

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

In addition, in the coming years, oral GLP-1 receptor agonists and injectable formulations that require less-frequent ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive ...

AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

The following is a summary of "Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide ...

The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...

Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 -- Announced new ...